While combination therapy ultimately is expected to rule the day in non-alcoholic steatohepatitis, much of the current focus is on which individual drug will be first to market for the unmet medical need. For Gilead Sciences Inc., however, disappointing results with its NASH candidates to date – and previous success with combo therapy in HIV and hepatitis C – appear to have it looking ahead to combination regimens for NASH.
Gilead Increasingly Seems Focused On Combo Therapy In NASH
At EASL, Gilead indicated it may not take any of its current NASH candidates forward as monotherapy options. Trial collaboration with Novo Nordisk may suggest pessimism toward selonsertib after Phase III disappointment.
